EPIX (ESSA Pharma Inc.) קצב צמיחת רווח למניה בשנה הנוכחית

ESSA Pharma Inc. (EPIX) is developing high-precision therapies to block tumor receptors, focusing on N-terminal domain inhibition in cases of resistance to standard treatment. The year-over-year earnings per share dynamics on GURU.Markets capture the current trend, where 0.00 records a new level. The company's strategy relies on its own pipeline tests and targeted alliances with the largest pharma behemoths.

Analyzing the annual earnings per share growth rate for the biotech issuer ESSA Pharma Inc. (EPIX), we assess the dynamics of net income per share. This metric measures the percentage change in EPS, neutralizing time gaps between quarterly reports. The current value of 0.00 reflects high capital sensitivity to operating expenses. For a company without commercial revenue, this indicator marks the cash burn rate prior to the publication of Phase 1/2 results. A negative or unstable curve confirms high pipeline risks.